Price History
Feb 9, 2026 — Mar 27, 2026Investment Snapshot
- Trading 54% below Graham Number ($14.61) — significant margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- Strong ROE of 36.1% with 75.2% net margin
- Revenue growing at 617% annually
CorMedix Inc. - Common Stock (CRMD) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $530 million . Key value metrics: P/E ratio 3.6, P/B ratio 1.31, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
CorMedix Inc. - Common Stock — Fundamental Analysis Summary
CorMedix Inc. - Common Stock (CRMD) is trading 54% below its Graham Number of $14.61 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 3.6x.
On financial health, CRMD shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 36.1% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.04.
StockPik's composite Value Score for CRMD is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CRMD reports a high gross margin of 92.1% (sector average: 33.5%) and a strong operating margin of 45.1%.
CRMD shows revenue growing at 617% year-over-year, with earnings growing at 1,009%.